Multi‐target therapy has been widely applied in clinics for the treatment of various cancers.[57, 58, 59, 60] As a dual‐targeted inhibitor of HIF‐1α and EZH2, DYB‐03 binds well to the dual targets and exhibits potent inhibitory activity. This evidence concerns the gene EZH2 and cancer.